Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | PGK2 | P07205 | 1/20 | 0.37 |
| ▸ | PGD | P52209 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17513026 | 0.98 | OR51E2 (0.40) | OR51E2PGK1PGK2 | |
| SCHEMBL5579171 | 0.88 | OR51E2 (0.40) | OR51E2PGK1PGK2PGD | |
| SCHEMBL29666492 | 0.87 | PGK1 (0.36) | OR51E2PGK1PGK2PGD | |
| SCHEMBL121274 | 0.85 | OR51E2 (0.42) | OR51E2PGK1PGK2 | |
| SCHEMBL6852791 | 0.81 | OR51E2 (0.39) | OR51E2PGK1PGK2 | |
| SCHEMBL316820 | 0.81 | CA4 (0.41) | OR51E2PGK1PGK2 | |
| Phosphoric Acid SCHEMBL4267407 | 0.80 | OR51E2 (0.42) | OR51E2PGK1PGK2PGD | |
| Lithium Ion SCHEMBL23387433 | 0.79 | CA1 (0.39) | OR51E2 | |
| SCHEMBL5467168 | 0.79 | CA1 (0.39) | OR51E2 | |
| SCHEMBL3847418 | 0.79 | CA1 (0.39) | OR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4346839-B1 | PHARMACEUTICAL COMPOSITIONS FOR CLINICAL NUTRITION | BAXTER INT (US) | 2025-03-26 | — | — | EP | claimed |
| CN-115279333-A | Composition or oat extract comprising avenanthramide and beta-glucan | 西姆莱斯股份公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-115243670-A | Cosmetic or pharmaceutical use of avenanthramide L | 西姆莱斯股份公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115243664-A | Compositions comprising avenanthramides for increasing skin permeability | 西姆莱斯股份公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115243669-A | Avenanthramide compositions with enhanced solubility comprising 4-hydroxybenzophenones | 西姆莱斯股份公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115209864-A | Compositions comprising avenanthramides or analogs thereof having improved stability | 西姆莱斯股份公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-107410304-B | Compositions comprising benzyl alcohol derivatives and other antimicrobially active compounds | 西姆莱斯有限公司 | 2020-06-12 | — | — | CN | disclosed |
| US-8278068-B2 | Ex vivo human skin model | SYMRISE AG (DE) | 2012-10-02 | — | — | US | disclosed |
| EP-1939279-B1 | Skin model | SYMRISE AG (DE) | 2012-07-11 | — | — | EP | disclosed |
| EP-2019316-B1 | Ex vivo human skin model | SYMRISE AG (DE) | 2011-05-11 | — | — | EP | disclosed |
| US-20100286102-A1 | Formulations comprising ceramides and/or pseudoceramides and (alpha-)bisabolol for combating skin damage | SYMRISE GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | disclosed |
| US-20090298113-A1 | EX VIVO HUMAN SKIN MODEL | SYMRISE GMBH & CO. KG (DE) | 2009-12-03 | — | — | US | disclosed |
| EP-1816998-B1 | FORMULATIONS COMPRISING CERAMIDES AND/OR PSEUDOCERAMIDES AND (ALPHA-)BISABOLOL FOR COMBATING SKIN DAMAGE | SYMRISE GMBH & CO KG (DE) | 2009-03-18 | — | — | EP | disclosed |
| EP-2019316-A2 | Ex vivo human skin model | Symrise GmbH & Co. KG (DE) | 2009-01-28 | — | — | EP | disclosed |
| EP-1939279-A1 | Skin model | Symrise GmbH & Co. KG (DE) | 2008-07-02 | — | — | EP | disclosed |
| US-20080138850-A1 | Skin Model | SYMRISE GMBH & CO. KG (DE) | 2008-06-12 | — | — | US | disclosed |
| EP-1927656-A1 | Skin model | Symrise GmbH & Co. KG (DE) | 2008-06-04 | — | — | EP | disclosed |
| EP-1816998-A1 | FORMULATIONS COMPRISING CERAMIDES AND/OR PSEUDOCERAMIDES AND (ALPHA-)BISABOLOL FOR COMBATING SKIN DAMAGE | Symrise GmbH & Co. KG (DE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070111920-A1 | Method for production of solid granulated with improved storage stability and abrasion resistance | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2007-05-17 | — | — | US | disclosed |
| WO-2006053912-A1 | FORMULATIONS COMPRISING CERAMIDES AND/OR PSEUDOCERAMIDES AND (ALPHA-)BISABOLOL FOR COMBATING SKIN DAMAGE | SYMRISE GMBH & CO. KG (DE) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286102-A1 | Formulations comprising ceramides and/or pseudoceramides and (alpha-)bisabolol for combating skin damage | CERT1, CERS2, SGMS1 | OR51E2 3554/4885PGK1 544/4885PGK2 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.